Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
暂无分享,去创建一个
Mitch Dowsett | Helen Anderson | Roger A'Hern | M. Dowsett | J. Salter | M. Wilcox | Z. Ghazoui | I. Smith | R. A’Hern | J. Bliss | A. Dunbier | H. Anderson | Ian Smith | Janine Salter | Zara Ghazoui | Anita Dunbier | Judith Bliss | A. Evans | John Robertson | Laura Robison | Isabel Pinhel | Lindsay Johnson | Tony Skene | Abigail Evans | Amanda Iskender | Maggie Wilcox | T. Skene | L. Johnson | J. Robertson | I. Pinhel | A. Iskender | L. Robison | A. Evans
[1] B. Fisher,et al. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. , 1989, Cancer research.
[2] P. Lønning,et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Kevin Camphausen,et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Dowsett,et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Dowsett,et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Dowsett,et al. Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer , 2011, Clinical Cancer Research.
[7] M. Dowsett,et al. Abstract S2-5: Molecular Profiling of Aromatase Inhibitor-Treated Post-Menopausal Breast Tumours Identifies Determinants of Response , 2010 .
[8] M. Dowsett,et al. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer , 2010, Breast Cancer Research and Treatment.
[9] T. Powles,et al. Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer , 2003, Breast Cancer Research and Treatment.
[10] A. Ashworth,et al. Molecular response to aromatase inhibitor treatment in primary breast cancer , 2007, Breast Cancer Research.
[11] Mitch Dowsett,et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.
[12] B. Calvo,et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Dowsett,et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] M. Dowsett,et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.